Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental injection aims to protect vision in High-Risk eye surgery

NCT ID NCT06926478

Summary

This early-stage study is testing whether a single injection of the drug adalimumab (Humira) given during an artificial cornea implant surgery is safe. The surgery, called a Boston Keratoprosthesis, is for people with severe, vision-threatening corneal damage who have few other options. Researchers will monitor 8 participants for 30 days after surgery to check for side effects and see if the injection might help reduce complications.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STEVENS-JOHNSON SYNDROME are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Massachusetts Eye and Ear

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.